KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) EBT: 2009-2024

Historic EBT for Neogenomics (NEO) over the last 16 years, with Dec 2024 value amounting to -$80.7 million.

  • Neogenomics' EBT fell 47.85% to -$26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$114.0 million, marking a year-over-year decrease of 42.79%. This contributed to the annual value of -$80.7 million for FY2024, which is 16.91% up from last year.
  • As of FY2024, Neogenomics' EBT stood at -$80.7 million, which was up 16.91% from -$97.1 million recorded in FY2023.
  • Over the past 5 years, Neogenomics' EBT peaked at -$14.1 million during FY2020, and registered a low of -$159.3 million during FY2022.
  • Moreover, its 3-year median value for EBT was -$97.1 million (2023), whereas its average is -$112.4 million.
  • Per our database at Business Quant, Neogenomics' EBT crashed by 957.00% in 2022 and then skyrocketed by 39.06% in 2023.
  • Neogenomics' EBT (Yearly) stood at -$14.1 million in 2020, then dropped by 7.25% to -$15.1 million in 2021, then crashed by 957.00% to -$159.3 million in 2022, then spiked by 39.06% to -$97.1 million in 2023, then rose by 16.91% to -$80.7 million in 2024.